Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
| ▸ | CFD | P00746 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.35 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5851464 | 0.89 | HDAC6 (0.43) | CNR2METCCR2MAPTTP53 | |
| SCHEMBL5849421 | 0.88 | NPC1 (0.40) | CNR2CCR2MAPTTP53MME | |
| SCHEMBL5849849 | 0.86 | TP53 (0.41) | CNR2CCR2MAPTALDH1A1TP53 | |
| SCHEMBL5849296 | 0.84 | CNR2 (0.60) | CNR2MAPTALDH1A1TSHR | |
| SCHEMBL5849609 | 0.83 | CNR2 (0.40) | CNR2CD38CCR2MAPTALDH1A1 | |
| SCHEMBL5849779 | 0.79 | TP53 (0.40) | CNR2CCR2MAPTTP53MME | |
| SCHEMBL5850690 | 0.74 | HDAC6 (0.44) | CNR2CFDMAPTALDH1A1TP53 | |
| SCHEMBL6220738 | 0.74 | CNR2 (0.45) | CNR2MAPTALDH1A1TSHR | |
| SCHEMBL27917520 | 0.74 | CNR2 (0.48) | CNR2MAPTTSHRTP53 | |
| SCHEMBL6222204 | 0.73 | CNR2 (0.49) | CNR2MAPTALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001912-B2 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | claimed |
| US-20050165040-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | claimed |
| US-7138408-B2 | HIV integrase inhibitors, pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060122211-A1 | HIV integrase inhibitors, pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| US-7001912-B2 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20050165040-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122211-A1 | HIV integrase inhibitors, pharmaceutical compositions and methods for their use | POLB, POLA1, TYMP | CNR2 3950/4885MET 4014/4885CD38 326/4885 |
| US-20050165040-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | POLB, APOBEC3C, IDH3A | CNR2 3906/4885MET 4024/4885CD38 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.